Integrum receives reimbursement code for Axor II™
Mölndal, Sweden, September 08, 2023 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that The Centers for Medicare and Medicaid Services (CMS) have granted the osseointegrated external prosthetic connection device Axor II™ a new reimbursement code. The new code, which is expected to take effect in October, is connected to a set reimbursement that will help to drive growth in the US.
The new CMS-specific code is granted based on a preliminary benefit category determination that the Axor™ II Ossteointegrated External Prosthetic Connection Device is used in addition to a lower extremity prosthesis and, therefore, falls under the Medicare benefit for artificial legs (prosthetics). Since the Axor™ II utilizes a standard 4-hole male/female mounting system, the OPRA™ Implant System can be connected to commercially available prosthetic systems that utilize this standardized connection method. The Axor™ II acts like a ski-binding and releases the prosthesis if overload occurs, reducing the risk of damage to the implant and the skeleton.
“The new reimbursement code marks the start of a formalized reimbursement process for our prosthetics. A formalized process enables prosthetists to, in a consistent way, apply for reimbursement and reduces the potential risk associated with using products without a dedicated code. We expect the new code will significantly improve our offering to prosthetists and help to drive growth when the code takes effect in October,” says Rickard Brånemark, CEO of Integrum.
Axor™ II was first approved under a Premarket Approval (PMA) application by the Food and Drug Administration (FDA) on December 18, 2020.
For more information please contact:
Rickard Brånemark, CEO. Phone: +46 708 461061, E-mail: rickard.branemark@integrum.se
Jörgen Svanström, CFO. Phone: +46 (0) 70 734 96 60, E-mail: jorgen.svanstrom@integrum.se
Certified Adviser
Erik Penser Bank is Certified Adviser
Integrum AB is a publicly traded company (INTEG B: Nasdaq First North exchange) based outside of Gothenburg, Sweden, with a US subsidiary in San Francisco, CA. Since 1990, osseointegration, the science behind the OPRA™ Implant System, has been helping individuals with amputations enjoy a dramatically improved quality of life. Thorough surgical experience gained over more than three decades, from more than 500 surgeries, in 14 countries, has led to the development of Integrum’s system for bone-anchored prostheses – a vastly superior alternative to the traditionally used socket prosthesis.